国投证券股份有限公司 关于广东肇庆星湖生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联交易之限 售股份解除限售并上市流通的核查意见 国投证券股份有限公司（以下简称"国投证券"或"独立财务顾问"）作为 广东肇庆星湖生物科技股份有限公司（以下简称"星湖科技"、"公司"或"上市 公司"）发行股份及支付现金购买资产并募集配套资金暨关联交易（以下简称"本 次重组"）的独立财务顾问，根据《上市公司重大资产重组管理办法》《上市公司 并购重组财务顾问业务管理办法》及《上海证券交易所股票上市规则》等相关法 规的要求，对星湖科技发行股份购买资产增发的限售股份解除限售并上市流通的 情况进行了认真、审慎的核查，具体核查情况如下： 一、本次限售股发行及股本变动情况 （一）限售股的核准发行情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准广东肇庆 星湖生物科技股份有限公司向广东省广新控股集团有限公司等发行股份购买资 产并募集配套资金的批复》（证监许可[2022]2870 号）核准，公司向广东省广新 控股集团有限公司发行 405,703,292 股股份、向宁夏伊品投资集团有限公司发行 223,379,0 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-038 广东肇庆星湖生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联 交易部分限售股上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为非公开发行股份；股票认购方式为网下， 上市股数为146,395,365股。 本次股票上市流通总数为146,395,365股。 本次股票上市流通日期为2025 年 7 月 29 日。 一、本次限售股上市类型 （一）股票发行核准情况 广东肇庆星湖生物科技股份有限公司（以下简称"上市公司"或 "公司"）发行股份及支付现金购买资产并募集配套资金暨关联交易 （以下简称"本次重组"或"本次交易"）于 2022 年 11 月 18 日收到 中国证券监督管理委员会（以下简称"中国证监会"）《关于核准广东 肇庆星湖生物科技股份有限公司向广东省广新控股集团有限公司等发 行股份购买资产并募集配套资金的批复》（证监许可[2022]2870 号）， 核准公司向广东省广新控股集团有限公司发行 ...

Group 1 - The fertilizer sector continues to rise, with significant stock price increases observed [1] - Both Boyuan Chemical (000683) and Qingsong Jianhua (600425) reached the daily limit increase [1] - Other companies such as Xuefeng Technology (603227), Kailong Co., Ltd. (002783), Luxi Chemical (000830), Hualu Hengsheng (600426), Yuntianhua (600096), and Xinghuo Technology (600866) also experienced price increases [1]

Core Viewpoint - The announcement details the release of share pledges by major shareholders of Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd., indicating a positive development in shareholder confidence and financial stability [1][2]. Group 1: Shareholder Information - As of the announcement date, the major shareholder, Ningxia Yipin Investment Group Co., Ltd. (Yipin Group), and its concerted actor, Tie Xiaorong, collectively hold 233,036,630 shares, accounting for 14.03% of the total share capital [1]. - Yipin Group holds 172,685,029 shares, representing 10.39% of the total share capital, while Tie Xiaorong holds 60,351,601 shares, which is 3.63% of the total share capital [1]. Group 2: Pledge Release Details - Yipin Group has released 89,351,604 shares from pledge, which is 51.74% of its pledged shares and 5.38% of the total share capital [1][2]. - Following the release of the pledge, Yipin Group and its concerted actors have no shares under pledge [1]. Group 3: Performance Commitment - In December 2023, Yipin Group and its concerted actors pledged 256,191,887 shares to Guangdong Province Guangxin Holdings Group Co., Ltd. as a guarantee for performance commitments [2]. - The performance commitments for the years 2022, 2023, and 2024 have been fulfilled, and there is no need for compensation to the listed company as of the end of the 2024 fiscal year [2]. Group 4: Future Plans - Yipin Group has confirmed that there are no plans for further share pledges following the release of the current pledges, and any future plans will be disclosed as necessary [3].

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-037 诺的保证，具体内容详见公司于 2023 年 12 月 28 日在上海证券交易 所网站（www.sse.com.cn）披露的《关于持股 5%以上股东部分股份 质押的公告》（公告编号：临 2023-051）。根据信永中和会计师事务 所（特殊普通合伙）出具的《关于宁夏伊品生物科技股份有限公司 2024 年 度 及 累 积 承 诺 业 绩 实 现 情 况 的 审 核 报 告 》 （XYZH/2025GZAA1B0214 号），宁夏伊品生物科技股份有限公司 2022、 2023、2024 年度的业绩承诺已经实现，广新集团、伊品集团以及铁 小荣关于伊品生物 2022、2023、2024 年度的业绩承诺得到了有效履 行，截至 2024 年度无需对上市公司进行补偿。 广东肇庆星湖生物科技股份有限公司 关于持股 5%以上股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 截至本公告披露日，广东肇庆星湖生物科技股份有限公司（以 下简称 ...

Core Viewpoint - The company, Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd., anticipates a significant increase in net profit for the first half of 2025, projecting a rise of over 50% compared to the same period last year [2][4]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 790 million to 850 million yuan, an increase of 283.83 million to 343.83 million yuan, representing a year-on-year growth of 56.07% to 67.93% [2][4]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between 760 million to 820 million yuan, an increase of 225.69 million to 285.69 million yuan, reflecting a year-on-year increase of 42.24% to 53.47% [2][4]. Group 2: Previous Year’s Performance - In the first half of 2024, the total profit was 648.20 million yuan, with a net profit attributable to shareholders of the parent company at 506.17 million yuan, and a net profit excluding non-recurring gains and losses at 534.31 million yuan [6]. Group 3: Reasons for Performance Change - The company achieved improved performance in the first half of 2025 through enhanced internal management and the implementation of "three precision management" initiatives, leading to increased efficiency in production and operations [8]. - Additionally, a decrease in the procurement costs of key raw materials contributed to the overall optimization of product costs, positively impacting profit growth [8]. Group 4: Shareholder Information - As of the announcement date, the major shareholder, Ningxia Yipin Investment Group Co., Ltd., and its associated party hold a total of 233,036,630 shares, accounting for 14.03% of the company's total share capital [11]. - The shareholder, Tie Xiaorong, has released a pledge on 57,043,761 shares, which is 94.52% of his pledged shares, representing 3.43% of the total share capital [11][12]. - After the release of the pledge, Tie Xiaorong has no pledged shares remaining, while the total pledged shares by him and his associates amount to 89,351,604 shares, which is 38.34% of their total holdings and 5.38% of the total share capital [12][14].

Group 1 - The company expects to achieve a net profit attributable to shareholders of the parent company for the first half of 2025 in the range of 790 million to 850 million yuan, representing an increase of 56.07% to 67.93% compared to the same period last year [1][2] - The estimated net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 760 million and 820 million yuan, which is an increase of 42.24% to 53.41% compared to the previous year [1][2] - The previous year's net profit attributable to shareholders of the parent company for the first half of 2024 was 506.17 million yuan, with a total profit of 648.20 million yuan [2] Group 2 - The company attributes the profit increase to improvements in production efficiency and a decrease in the procurement costs of major raw materials during the reporting period, leading to optimized overall product costs [2] - The earnings per share for the first half of 2024 was reported at 0.3047 yuan [2]

Core Viewpoint - The announcement details the release of share pledges by a major shareholder of Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd., indicating a positive development in the company's shareholder structure and financial commitments [1][2]. Shareholder Information - As of the announcement date, the major shareholder, Ningxia Yipin Investment Group Co., Ltd. and its concerted actor, Tie Xiaorong, collectively hold 233,036,630 shares, accounting for 14.03% of the total share capital of the company [1]. - Tie Xiaorong has released 57,043,761 shares from pledge, which represents 94.52% of his pledged shares and 3.43% of the company's total share capital [2]. Pledge Details - After the release of the pledge, Tie Xiaorong has no remaining pledged shares, while the total pledged shares by him and his concerted actors amount to 89,351,604 shares, which is 38.34% of their total holdings and 5.38% of the company's total share capital [1][2]. - The pledged shares were originally provided to Guangdong Guangxin Holdings Group Co., Ltd. as a guarantee for performance commitments [1]. Performance Commitments - The performance commitments for Ningxia Yipin Biotechnology Co., Ltd. for the years 2022, 2023, and 2024 have been effectively fulfilled, and as of the end of the 2024 fiscal year, there is no need for compensation to the listed company [1].

[Core Performance Forecast Data](index=1&type=section&id=Core%20Performance%20Forecast%20Data) The company forecasts H1 2025 net profit attributable to shareholders and non-recurring net profit to significantly increase H1 2025 Performance Forecast Summary | Metric | H1 2025 Forecast (million CNY) | H1 2024 (Prior Period) (million CNY) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 790 - 850 | 506.17 | 56.07% - 67.93% | | **Non-recurring Net Profit Attributable to Shareholders** | 760 - 820 | 534.31 | 42.24% - 53.47% | - This performance forecast applies to scenarios where net profit increases by over **50%** year-on-year[2](index=2&type=chunk) - The financial data in this performance forecast is unaudited by a certified public accountant[3](index=3&type=chunk) [Prior Period Performance Review](index=2&type=section&id=Prior%20Period%20Performance%20Review) This section reviews H1 2024 key financial data, including net profit and EPS, providing the baseline for current period growth H1 2024 Key Financial Data | Metric | H1 2024 Amount (million CNY) | | :--- | :--- | | Total Profit | 648.20 | | Net Profit Attributable to Parent Company Owners | 506.17 | | Non-recurring Net Profit Attributable to Parent Company Owners | 534.31 | | Earnings Per Share (CNY) | 0.3047 | [Analysis of Performance Change Reasons](index=2&type=section&id=Analysis%20of%20Performance%20Change%20Reasons) H1 2025 performance growth is primarily driven by optimized internal management and reduced raw material costs - The company achieved tangible results in improving production and operational efficiency through optimized internal management and "Three-Excellence Management" initiatives[5](index=5&type=chunk) - Reduced procurement costs for major raw materials during the reporting period further optimized overall product costs, positively impacting profit growth[5](index=5&type=chunk) [Risk Warning and Other Disclosures](index=3&type=section&id=Risk%20Warning%20and%20Other%20Disclosures) This unaudited performance forecast is a preliminary estimate, with final data subject to the officially disclosed H1 2025 semi-annual report - This performance forecast is a preliminary calculation by the company's finance department based on professional judgment and is unaudited by a certified public accountant[6](index=6&type=chunk) - As of the announcement date, no significant uncertainties affecting the accuracy of this performance forecast have been identified[6](index=6&type=chunk) - Investors are reminded that specific and accurate financial data will be subject to the officially disclosed H1 2025 semi-annual report, and to be aware of investment risks[7](index=7&type=chunk)

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-036 本次解除质押完成后，铁小荣持有公司股份累计质押数量为 0 股； 铁小荣及其一致行动人累计质押数量为 89,351,604 股，占其合计持 股数量的 38.34%，占公司总股本的 5.38%。 2025 年 7 月 10 日，公司收到股东铁小荣《关于所持星湖科技股 份解押的告知函》，获悉其将持有公司的部分股份办理了解除质押手 续，具体情况如下： 一、 本次股份解除质押的具体情况 2023 年 12 月，股东铁小荣将持有公司的 99,826,581 股股份质 押给广东省广新控股集团有限公司（以下简称"广新集团"）作为业 绩承诺的保证，具体内容详见公司于 2023 年 12 月 28 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于持股 5%以上股东部分 股份质押的公告》（公告编号：临 2023-051）。根据信永中和会计师 事务所（特殊普通合伙）出具的《关于宁夏伊品生物科技股份有限公 司 2024 年 度 及 累 积 承 诺 业 绩 实 现 情 况 的 审 核 报 告 》 广东肇庆星湖生物科技股份有限公司 关于持股 5 ...